Help Your Patients Achieve Their Reproductive Goals

With NxGen MDx you can improve IVF efficiency with

  • Carrier Screening
  • Preimplantation Genetic Testing
  • Non-Invasive Prenatal Screening
  • Hereditary Cancer Testing
  • Vaginal Microbiome Testing

What is NatalCare?

NatalCare is NxGen MDx’s curation philosophy for our carrier screening, PGT, NIPS, hereditary cancer, and vaginosis products which focuses on improving pregnancy and newborn outcomes. NxGen goes above and beyond with actionable solutions that streamline processes for providers and see patients through their entire reproductive journey.

Carrier Screening

“Carrier screening paradigms should be ethnic and population neutral and more inclusive of diverse populations to promote equity and inclusion."
-The American College of Medical Genetics and Genomics1

  • NxGen’s Super Panel was intelligently curated to focus on clinical actionability.
  • Simplified support for partner testing and PGT-M for at-risk couples.

The Super Panel has an at-risk couple rate of 1 in 23, one of the highest on the market.

Carrier Screening

Preimplantation Genetic Testing (PGT)

NxGen MDx offers PGT-A, PGT-M, and PGT-SR options for your patients to increase pregnancy rates through the selection of chromosomally normal embryos and to help prevent passing on identified inherited genetic conditions.

  • Industry-leading high-resolution sequencing for results you can trust.
  • Innovative bioinformatics pipeline designed to reduce false positives and increase the number of transferable embryos.
Preimplantation Genetic Testing (PGT)

Non-Invasive Prenatal Screening (NIPS)

"Traditional diagnostic testing or screening for aneuploidy should be offered to all patients who have had preimplantation genetic testing-aneuploidy (PGT-A), in accordance with recommendations for all pregnant patients."
-The American College of Obstetricians and Gynecologists2

  • No restrictions for ART pregnancies, twin pregnancies, egg donors, surrogates, or bone marrow/organ transplant recipients.
  • No-Call Rate of 0.3%.
Non-Invasive Prenatal Screening (NIPS)

Hereditary Cancer Testing

“Women who carry pathogenic gene variants that place them at high risk for cancer should be educated and counseled about preimplantation genetic testing.”
-The American Society for Reproductive Medicine3

  • Hereditary cancer testing can help identify individuals who may benefit from fertility preservation and PGT-M for cancer-associated genes.
  • Streamlined support includes pre- and post-test genetic counseling and electronic tools to identify at-risk individuals.
Hereditary Cancer Testing

Vaginal Microbiome Testing

An imbalance in the vaginal microbiome is associated with negative reproductive outcomes including:

  • Infertility4,5
  • Suboptimal IVF outcomes6,7
  • Miscarriage8
  • Preterm labor and delivery7
  • Postpartum complications for the infant9
Vaginal Microbiome Testing
  1. Gregg AR, Aarabi M, Klugman S, Leach NT, Bashford MT, Goldwaser T, et al. Screening for autosomal recessive and X-linked conditions during pregnancy and preconception: a practice resource of the American College of Medical Genetics and Genomics (ACMG). Genet Med. 2021 Oct;23(10):1793–806.
  2. Preimplantation Genetic Testing: ACOG Committee Opinion, Number 799. Obstet Gynecol. 2020 Mar;135(3):e133–7.
  3. Chen L-M, Blank SV, Burton E, Glass K, Penick E, Woodard T. Reproductive and Hormonal Considerations in Women at Increased Risk for Hereditary Gynecologic Cancers: Society of Gynecologic Oncology and American Society for Reproductive Medicine Evidence-Based Review. Gynecol Oncol. 2019 Dec;155(3):508–14.
  4. Ravel J, Moreno I, Simón C. Bacterial vaginosis and its association with infertility, endometritis, and pelvic inflammatory disease. Am J Obstet Gynecol. 2021 Mar;224(3):251–7.
  5. Mastromarino P, Hemalatha R, Barbonetti A, Cinque B, Cifone MG, Tammaro F, et al. Biological control of vaginosis to improve reproductive health. Indian J Med Res. 2014 Nov;140 Suppl:S91-97.
  6. Fu M, Zhang X, Liang Y, Lin S, Qian W, Fan S. Alterations in Vaginal Microbiota and Associated Metabolome in Women with Recurrent Implantation Failure. mBio. 11(3):e03242-19.
  7. Koedooder R, Singer M, Schoenmakers S, Savelkoul PHM, Morré SA, de Jonge JD, et al. The vaginal microbiome as a predictor for outcome of in vitro fertilization with or without intracytoplasmic sperm injection: a prospective study. Hum Reprod. 2019 Jun 4;34(6):1042–54.
  8. Işik G, Demirezen Ş, Dönmez HG, Beksaç MS. Bacterial vaginosis in association with spontaneous abortion and recurrent pregnancy losses. J Cytol. 2016 Sep;33(3):135–40.
  9. Dingens AS, Fairfortune TS, Reed S, Mitchell C. Bacterial vaginosis and adverse outcomes among full-term infants: a cohort study. BMC Pregnancy Childbirth. 2016 Sep 22;16(1):278.